Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
JERUSALEM, Dec. 5, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in the development of inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices unit, announced today the appointment of Prof. Michael Schön to its Scientific Advisory Board (SAB).
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), joins Scinai Immunotherapeutics' Scientific Advisory Board
Prof. Michael Schön is a distinguished Professor and Director of the Department of Dermatology, Venereology, and Allergology at the University Medical Center Göttingen. He also serves as Vice Dean and Deputy Director for Research and Teaching and is the former director of the Lower Saxony Institute of Occupational Dermatology. Prof. Schön has been recognized with numerous awards for his groundbreaking research on immune reactions in inflammation. From 2011 to 2024, he was the Editor-in-Chief of the Journal of the German Dermatological Society. Currently, he holds the position of Secretary General and Vice President of the European Dermatology Forum (EDF).
Prof. Schön earned his MD in Medicine from the University of Ulm, Germany. He has worked at the Free University of Berlin, Harvard Medical School and the universities of Düsseldorf and Magdeburg. Before his appointment at the University Medical Center Göttingen, he held a professorship in Experimental Biomedicine at the University of Würzburg. Michael has further qualifications in dermatopathology, allergology, immunology and health economics.
Prof. Schön commented: "It is a great pleasure and honor for me to be part of the advisory board for Scinai and to contribute to the success of their highly innovative pipeline. In many areas of chronic inflammatory skin diseases, but also in other organ systems with immunologically mediated diseases, there is a significant unmet medical need. In my view, Scinai's targeted immunological therapeutic approaches have excellent potential to provide exciting innovation in various areas of precision inflammation medicine."
Amir Reichman, CEO of Scinai, stated: "We are thrilled to welcome Prof. Schön, a world-class expert in dermatology, particularly in psoriasis and atopic dermatitis, to our Scientific Advisory Board. Michael's extensive experience as a dermatologist, having treated thousands of patients, and as a researcher with over 440 scientific publications in top-rated journals, along with his proven track record in drug development and clinical research, will be invaluable to Scinai. His insights will be crucial as we advance our pipeline of innovative I&I biological products. Additionally, I would like to congratulate Dr. Jonathan Sadeh, a member of our Scientific Advisory Board, on his recent appointment as Chief Scientific Officer and Chief Medical Officer of Bausch Health. We wish Jonathan great success in his new role. These two recent appointments to our Scientific Advisory Board are a testament to the high caliber of talent advising our R&D team and board of directors."
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development projects.
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. Examples of such statements include, but are not limited to, the potential of Scinai's NanoAb program and the advancement of its pipeline of innovative I&I biological products. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; the risk that the Company will not successfully advance its pipeline of innovative I&I biological products; the risk that the Company will otherwise be unable to remain compliant with the continued listing requirements of Nasdaq; a delay in the commencement and results of pre-clinical and clinical studies, including the Phase 1/2a study for psoriasis, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on May 15, 2024, and the Company's subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason.
